HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
– These cardiovascular medicines have the potential to address a significant unmet medical need for over half a million Canadians
– HLS will leverage existing organizational capabilities and commercial infrastructure
– Already approved and commercially available in the U.S. and Europe, NEXLETOL/NEXLIZET are under regulatory review in Canada with a decision expected later this year
– Deal terms include $1 million paid upfront and additional milestone payments tied to achievement of regulatory, pricing, reimbursement and commercial sales objectives
TORONTO, May 8, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into an agreement with Esperion Therapeutics Inc. ("Esperion") (NASDAQ: ESPR) to in-license and commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada. All financial figures are in U.S. dollars unless otherwise stated.
In Q4 2024, Esperion submitted New Drug Submissions to Health Canada for both NEXLETOL and NEXLIZET 1. Under this agreement, HLS will be responsible for obtaining Health Canada approval, which is expected by the end of 2025. NEXLETOL and NEXLIZET are oral medications currently available in the U.S. and several European countries. Initially approved by the U.S. Food and Drug Administration in 2020 to help reduce low-density lipoprotein cholesterol ("LDL-C") levels, their labels were expanded in 2024 to include broader indications for cardiovascular risk reduction in patients who are unable to take recommended statin therapy, supported by data from the CLEAR Outcomes trial.
Current estimates suggest there are over half a million Canadians who could potentially benefit from NEXLETOL or NEXLIZET. This includes patients with elevated LDL-C levels and who are either statin intolerant or who are not at their LDL-C goal despite being on combination therapy with statins and ezetimibe.
"We look forward to working with Esperion to bring these innovative treatments to the many Canadians suffering from, or at risk of, cardiovascular disease," said Craig Millian, CEO at HLS. "Adding NEXLETOL and NEXLIZET to the HLS product portfolio is aligned with our stated BD strategy and will strengthen our position in the Canadian cardiovascular market."
"We are pleased to partner with HLS to provide advanced cardiovascular treatment options to patients across Canada," said Sheldon Koenig, President and CEO of Esperion. "HLS is highly regarded within Canada for their strong capabilities and relationships in the cardiovascular therapeutic area. This collaboration furthers Esperion's commitment to addressing cardiovascular and cardiometabolic diseases globally."
The agreement includes an upfront payment of $1 million, an additional $1 million upon Health Canada approval, customary royalties on future sales, and potential milestone payments tied to pricing and reimbursement and achievement of significant commercial sales targets. HLS will fund all upfront and milestone-based payments, along with associated launch costs, through existing cash reserves without requiring additional financing. Furthermore, the company intends to leverage current commercial infrastructure and does not anticipate a significant increase in operating expenses will be required.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
ABOUT ESPERION THERAPEUTICS
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and https://x.com/EsperionIncX.
REFERENCES
1: NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) are the commercial brand names in the U.S. The brand names in Canada to be confirmed upon approval by Health Canada.
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated May 7, 2025, both of which have been filed on SEDAR+ and can be accessed at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE HLS Therapeutics Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Why AppFolio Stock Rocked the Market on Tuesday
One quite active stock mover on a forgettable Tuesday for the market was specialized business software developer AppFolio (NASDAQ: APPF). The company's shares saw a robust rise of almost 5% across the trading day, thanks to a pair of insider stock buys disclosed in regulatory filings. On that day, the S&P 500 (SNPINDEX: ^GSPC) also rose but by nowhere near as much, inching up to close the day 0.6% higher. A pair of very familiar stock buyers The two AppFolio folks snapping up shares of the company were members of its board of directors, Timothy Bliss and Casey Donald. Of the pair, Bliss was the more assertive, as he amassed 22,000 shares in a series of buys between last Thursday and the following Monday. The per-share price he paid for each of these blocks ranged from $215.28 to $218.73. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » As for Donald, his buying activity was more muted and concentrated. In a single purchase made last Friday, he snapped up 4,000 shares, paying an average of $217.73 apiece for the privilege. Shares of AppFolio, a software-as-a-service (SaaS) company that focuses on the real estate market, have seen something of an upswing lately. In no small part, this is a recovery from a sell-off following the company's first-quarter earnings release, published in late April. Although it posted solid growth on the top line, its net income fell, and it missed analyst estimates for both metrics. Lofty expectations We should bear in mind that investor expectations for the often-prosperous SaaS segment can be awfully high. Often, folks invested in industry titles demand not only strong, across-the-board growth; they insist on crushing beats too. To me, AppFolio is still doing very well in its niche, and remains robustly profitable despite that recent bottom-line dip. I think those insider buys were smart. Should you invest $1,000 in AppFolio right now? Before you buy stock in AppFolio, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AppFolio wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Vancouver Sun
2 hours ago
- Vancouver Sun
Opinion: Living with multiple sclerosis is difficult. Living in B.C. makes it harder
I was diagnosed with multiple sclerosis in September 2024. MS is a chronic, progressive disease of the central nervous system that can affect your vision, balance, cognition, and mobility. My diagnosis was a gut-punch — after years of hard work building my filmmaking career, my future was suddenly in jeopardy. The diagnosis took a predictably emotional toll on my family and me. Plans we had made for the future were now question marks. Through the support of my family and friends, plus lots of therapy, I've accepted my diagnosis for what it is — a totally unexpected development in my life. MS is unpredictable and deeply personal — no two people experience it the same way. But while MS is unpredictable, access to treatment shouldn't be. Yet in B.C., it is. A daily roundup of Opinion pieces from the Sun and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Informed Opinion will soon be in your inbox. Please try again Interested in more newsletters? Browse here. B.C. is the only province in Canada that does not provide public coverage for Health Canada-approved, anti-CD20 therapies for relapsing MS — ofatumumab and ocrelizumab. These treatments reduce relapses, delay progression, and improve long-term health outcomes. Unless you have special private insurance or happen to be employed by the provincial government (which covers these drugs under its internal employee drug plan), the out-of-pocket costs of these drugs are prohibitive for people such as me. When I was diagnosed with MS, my neurologist explained that ofatumumab was the most appropriate therapy for me — not only because of its strong results, but because some of the other treatments could worsen my Type-1 diabetes and related complications such as diabetic retinopathy. But because PharmaCare does not cover ofatumumab, I'm instead being offered alternative drugs that are less effective, and that will worsen my diabetes control. Thankfully, I was able to access ofatumumab through a six-month bridge program offered by the manufacturer, and I began treatment this past January. I'm happy to report that I've tolerated the drug extremely well. It's exactly what I need to manage my MS and keep living a normal, productive and full life. But the bridge program ends in a matter of days. I'm facing the very real possibility of having to switch to a higher-risk alternative simply because of where I live in Canada. My family and I are now having conversations about leaving the province. This is an equity issue, plain and simple. For people such as me, this doesn't just affect our health — it impacts our ability to plan ahead and to build stable lives. MS often strikes during our most productive years, and it can force people out of the workforce far earlier than they should be. However, early, effective treatment helps people stay healthier, more independent, and more engaged in their communities. At the very least, those of us who can't take the publicly funded options due to other health conditions should not be left behind. The alternative shouldn't be settling for a drug that is clinically inappropriate for me, simply because it's cheaper for the system. That's not good medicine, and it's certainly not good policy. I'm not asking for special treatment. I'm asking for fair treatment. For myself and for every British Columbian living with MS. I'm asking for the ability to manage my disease based on what works for me, not on what PharmaCare happens to cover. I'm lucky to have mild symptoms and a supportive medical team, but even still, the gruelling process of trying to access the right treatment has been emotionally exhausting, adding a layer of grief during an already difficult time. I urge the B.C. government to fund all Health Canada-approved MS treatments through PharmaCare and ensure that people across this province can access the medications they need, when they need them. Teresa Alfeld is a film director based in Vancouver. She was diagnosed with relapsing MS in 2024 and diagnosed with Type 1 diabetes in 1994.
Cision Canada
2 hours ago
- Cision Canada
CT REAL ESTATE INVESTMENT TRUST ANNOUNCES RENEWAL OF BASE SHELF PROSPECTUS AND ATM PROGRAM
TORONTO, /CNW/ - CT Real Estate Investment Trust (TSX: ("CT REIT" or the "REIT") announced today that it has renewed its existing base shelf prospectus and filed and obtained a receipt for a short form base shelf prospectus (the "Shelf Prospectus"), which is valid until July 10, 2027. The REIT also announced today that it has renewed its at-the-market equity program (the "ATM Program") that allows the REIT to issue up to $100 million of REIT trust units ("Units") from treasury to the public from time to time, at the REIT's discretion. Any Units sold in the ATM Program will be sold through the Toronto Stock Exchange (the "TSX"), or any other marketplace on which the Units are listed, quoted or otherwise traded in Canada, at the prevailing market price at the time of sale. There is no certainty that any Units will be offered or sold under the ATM Program. The ATM Program will be effective until the earlier of (i) the issuance and sale of an aggregate of $100 million of Units reserved under the ATM Program, (ii) the receipt for the Shelf Prospectus ceasing to be effective in accordance with applicable securities laws (which is expected to occur on July 10, 2027), and (iii) the termination of the Distribution Agreement (as defined below) in accordance with its terms. The REIT intends to use the net proceeds from the ATM Program, if any, to repay indebtedness, for working capital, for acquisitions and development activity and for general business purposes. As Units distributed under the ATM Program will be issued and sold at the prevailing market price at the time of the sale, prices may vary among purchasers during the period of the distribution. Distributions of the Units under the ATM Program (if any) will be led by CIBC Capital Markets and BMO Capital Markets pursuant to the terms of an equity distribution agreement dated June 10, 2025 (the "Distribution Agreement"). The volume and timing of any distributions of Units under the ATM Program will be determined in the REIT's sole discretion. Sales of Units under the ATM Program, if any, will be made through "at-the-market distributions" as defined in National Instrument 44-102 Shelf Distributions. The TSX has conditionally approved the listing of the Units that may be sold under the ATM Program. The offering of Units under the ATM Program will be made pursuant to a prospectus supplement dated June 10, 2025 (the "Prospectus Supplement") to the REIT's Shelf Prospectus. The Prospectus Supplement, the Shelf Prospectus and the Distribution Agreement were filed with the securities commissions in each of the provinces and territories of Canada and are available on the REIT's SEDAR+ profile at These documents may be requested by contacting BMO Nesbitt Burns Inc. by mail at Brampton Distribution Centre, 9195 Torbram Road, Brampton, Ontario, L6S 6H2, Attn: The Data Group of Companies, by email at [email protected] or by telephone at 905-791-3151 ext. 4312, or by contacting CIBC Capital Markets, 161 Bay Street, 5th Floor, Toronto, ON M5J 2S8 or by telephone at 416-956-6378 or by email at [email protected] by providing an email address or address, as applicable. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Units have not been registered under the United States Securities Act of 1933 (the "U.S. Securities Act") or any state securities laws. Accordingly, the Units may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the REIT, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. About CT Real Estate Investment Trust CT REIT is an unincorporated, closed-end real estate investment trust formed to own income-producing commercial properties located primarily in Canada. Its portfolio is comprised of over 375 properties totalling more than 31 million square feet of GLA, consisting primarily of net lease single-tenant retail properties located across Canada. Canadian Tire Corporation, Limited is CT REIT's most significant tenant. For more information, visit Forward-Looking Statements This press release contains statements and other information that constitute "forward-looking information" or "forward-looking statements" under applicable securities legislation (collectively, "forward-looking statements") that reflect CT REIT's current expectations relating to future events, including but not limited to statements with respect to the distribution of Units, if any, under the ATM Program and the benefits associated therewith and the use of proceeds, if any, of the ATM Program. By its very nature, forward-looking information requires the use of estimates and assumptions and is subject to inherent risks and uncertainties. It is possible that CT REIT's assumptions, estimates, analyses, beliefs, and opinions are not correct, and that CT REIT's expectations and plans will not be achieved. For more information on the risks, uncertainties, factors and assumptions that could cause CT REIT's actual results to differ from current expectations, refer to the factors discussed under "Risk Factors" in CT REIT's Shelf Prospectus and Prospectus Supplement, each as amended or supplemented, and the documents incorporated by reference therein, all of which are available at and at CT REIT does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by it or on its behalf, to reflect new information, future events or otherwise, except as required by applicable securities laws.
